|
US5578550A
(en)
|
1993-10-08 |
1996-11-26 |
American Cyanamid Company |
Herbicidal oxadiazole carbonamide compounds
|
|
JP3402153B2
(ja)
|
1997-10-01 |
2003-04-28 |
凸版印刷株式会社 |
耐水性および剛性に優れた含浸紙
|
|
US6998233B2
(en)
|
1998-06-26 |
2006-02-14 |
Sunesis Pharmaceuticals, Inc. |
Methods for ligand discovery
|
|
US7214487B2
(en)
|
1998-06-26 |
2007-05-08 |
Sunesis Pharmaceuticals, Inc. |
Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
|
|
AU2573102A
(en)
|
2000-11-21 |
2002-06-03 |
Sunesis Pharmaceuticals Inc |
An extended tethering approach for rapid identification of ligands
|
|
US9157875B2
(en)
|
2001-05-16 |
2015-10-13 |
Benjamin P. Warner |
Drug development and manufacturing
|
|
US20080220441A1
(en)
|
2001-05-16 |
2008-09-11 |
Birnbaum Eva R |
Advanced drug development and manufacturing
|
|
CN101252991B
(zh)
|
2005-06-28 |
2012-10-03 |
住友化学株式会社 |
过氧化物分解催化剂
|
|
JP5143841B2
(ja)
|
2006-10-10 |
2013-02-13 |
ロス アラモス ナショナル セキュリティー，エルエルシー |
高度な薬物開発及び製造
|
|
WO2010072228A1
(en)
|
2008-12-22 |
2010-07-01 |
Xigen S.A. |
Novel transporter constructs and transporter cargo conjugate molecules
|
|
AR078793A1
(es)
|
2009-10-27 |
2011-12-07 |
Orion Corp |
Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
|
|
EP2606045B1
(en)
|
2010-08-16 |
2016-01-06 |
Boehringer Ingelheim International GmbH |
Oxadiazole inhibitors of leukotriene production
|
|
EP2609092B1
(en)
|
2010-08-26 |
2015-04-01 |
Boehringer Ingelheim International GmbH |
Oxadiazole inhibitors of leukotriene production
|
|
CA2817380C
(en)
|
2010-12-16 |
2019-06-04 |
Genentech, Inc. |
Diagnosis and treatments relating to th2 inhibition
|
|
AR089853A1
(es)
|
2012-02-01 |
2014-09-24 |
Boehringer Ingelheim Int |
Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
|
|
TWI573792B
(zh)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
|
CN104662018B
(zh)
*
|
2012-04-20 |
2017-10-24 |
阿迪维纳斯治疗有限公司 |
取代的杂双环化合物、组合物及其医疗应用
|
|
CA2881070A1
(en)
|
2012-10-26 |
2014-05-01 |
F. Hoffmann-La Roche Ag |
Inhibitors of bruton's tyrosine kinase
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
RS59853B1
(sr)
|
2014-03-14 |
2020-02-28 |
Novartis Ag |
Molekuli anti-lag-3 antitela i njihove upotrebe
|
|
EP3125920B1
(en)
|
2014-04-04 |
2020-12-23 |
Del Mar Pharmaceuticals |
Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
|
|
KR101635848B1
(ko)
|
2014-04-14 |
2016-07-05 |
한국세라믹기술원 |
탄소 비결합성 금속 나노입자가 함유된 잉크 기제 제조 방법 및 금속 나노입자가 분산된 잉크
|
|
KR101582834B1
(ko)
|
2014-04-14 |
2016-01-08 |
한국세라믹기술원 |
비수계 그래핀 코팅액 제조 방법
|
|
BR112017006305B1
(pt)
|
2014-10-06 |
2024-02-20 |
Merck Patent Gmbh |
Compostos heteroarila, seus usos, e composição farmacêutica
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CA2988436A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
JP6954994B2
(ja)
|
2016-08-16 |
2021-10-27 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
可逆性ｂｔｋ阻害剤としてのオキソ−イミダゾピリジン及びその使用
|
|
GB201614134D0
(en)
|
2016-08-18 |
2016-10-05 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2018098275A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
CA3042294A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
UY37559A
(es)
|
2017-01-06 |
2018-05-31 |
Pharmacyclics Llc |
Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
|
|
JP7217712B2
(ja)
|
2017-01-24 |
2023-02-03 |
シーエスピーシー ジョォンチィ ファーマシューティカル テクノロジー （シージアジョァン）カンパニー，リミテッド |
Ｌｓｄ１阻害剤、その製造方法及び応用
|
|
JOP20190233A1
(ar)
|
2017-04-14 |
2019-10-02 |
Biogen Ma Inc |
نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
|
|
ES2988261T3
(es)
|
2017-06-29 |
2024-11-19 |
G1 Therapeutics Inc |
Formas mórficas de GIT38 y métodos de fabricación de las mismas
|
|
CN109422752B
(zh)
|
2017-09-03 |
2023-04-07 |
上海美志医药科技有限公司 |
一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
|
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
US20210002295A1
(en)
|
2017-12-14 |
2021-01-07 |
Dana-Farber Cancer Institute, Inc. |
Small molecule degraders that recruit dcaf15
|
|
EP3746426A4
(en)
|
2018-01-29 |
2021-12-29 |
Dana Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
WO2019160915A1
(en)
|
2018-02-14 |
2019-08-22 |
Dana-Farber Cancer Institute, Inc. |
Irak degraders and uses thereof
|
|
EP3752491A4
(en)
|
2018-02-15 |
2021-12-01 |
Nuvation Bio Inc. |
HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS
|
|
US20200121684A1
(en)
|
2018-03-10 |
2020-04-23 |
Yale University |
Modulators of btk proteolysis and methods of use
|
|
US11028088B2
(en)
|
2018-03-10 |
2021-06-08 |
Yale University |
Modulators of BTK proteolysis and methods of use
|
|
WO2019183523A1
(en)
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
|
US11613543B2
(en)
*
|
2018-03-26 |
2023-03-28 |
Novartis Ag |
Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
|
|
WO2019186358A1
(en)
|
2018-03-26 |
2019-10-03 |
Novartis Ag |
3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
|
|
CN115192726A
(zh)
|
2018-04-03 |
2022-10-18 |
深圳大学 |
免疫激动剂靶向化合物的合成及其应用
|
|
TW202016097A
(zh)
|
2018-05-14 |
2020-05-01 |
美商百健Ｍａ公司 |
布魯頓氏酪胺酸激酶之抑制劑
|
|
WO2020018788A1
(en)
|
2018-07-20 |
2020-01-23 |
Dana-Farber Cancer Institute, Inc. |
Degraders that target proteins via keap1
|
|
AU2019326865A1
(en)
|
2018-08-28 |
2021-03-25 |
Merck Patent Gmbh |
Fused imidazopyridines as reversible inhibitors of bruton's tyrosine kinase (BTK)
|
|
BR112021007115A2
(pt)
|
2018-10-15 |
2021-07-20 |
Nurix Therapeutics, Inc. |
compostos bifuncionais para dedradação de btk por meio da via de proteossoma de ubiquitina
|
|
BR112021010484A2
(pt)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics, Inc. |
Degradadores de irak e usos dos mesmos
|
|
WO2020127377A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/il-7 molecule
|
|
WO2020127369A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional molecule directed against human pd-1
|
|
CA3122914A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/sirp.alpha. molecule
|
|
WO2020167518A1
(en)
|
2019-02-13 |
2020-08-20 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
SG11202108794RA
(en)
|
2019-02-15 |
2021-09-29 |
Bristol Myers Squibb Co |
Substituted amide compounds useful as farnesoid x receptor modulators
|
|
WO2020206035A1
(en)
|
2019-04-01 |
2020-10-08 |
G1 Therapeutics, Inc. |
Treatment of cdk4/6 inhibitor resistant neoplastic disorders
|
|
US12240838B2
(en)
|
2019-05-15 |
2025-03-04 |
Biogen Ma Inc. |
Inhibiting agents for Bruton's tyrosine kinase
|
|
WO2020252397A1
(en)
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
|
US20220372017A1
(en)
|
2019-06-24 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Hck degraders and uses thereof
|
|
CN114174299B
(zh)
*
|
2019-07-26 |
2024-10-25 |
百济神州有限公司 |
通过btk抑制剂与e3连接酶配体缀合对布鲁顿氏酪氨酸激酶(btk)的降解以及使用方法
|
|
CN114521196A
(zh)
*
|
2019-09-16 |
2022-05-20 |
诺华股份有限公司 |
双官能团降解剂及其使用方法
|
|
WO2021087112A1
(en)
|
2019-10-30 |
2021-05-06 |
Biogen Ma Inc. |
Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
|
|
JP7646671B2
(ja)
|
2019-12-23 |
2025-03-17 |
バイオジェン・エムエイ・インコーポレイテッド |
Ｂｔｋ阻害剤
|
|
WO2021180103A1
(en)
|
2020-03-11 |
2021-09-16 |
Beigene, Ltd. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
EP4146655A4
(en)
|
2020-04-30 |
2024-07-31 |
BeiGene, Ltd. |
DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE
|
|
EP4192587A1
(en)
|
2020-08-07 |
2023-06-14 |
Biogen MA Inc. |
Btk inhibitors
|
|
US20240246977A1
(en)
|
2020-12-31 |
2024-07-25 |
Beigene Switzerland Gmbh |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use
|
|
EP4333899A1
(en)
|
2021-05-05 |
2024-03-13 |
Biogen MA Inc. |
Compounds for targeting degradation of bruton's tyrosine kinase
|
|
KR20240025529A
(ko)
|
2021-06-21 |
2024-02-27 |
베이진 스위찰랜드 게엠베하 |
(r)-글루타르이미드 crbn 리간드 및 사용 방법
|
|
WO2023110138A1
(en)
|
2021-12-17 |
2023-06-22 |
Zedira Gmbh |
Inhibitors of transglutaminases
|
|
RS66138B1
(sr)
|
2021-06-30 |
2024-11-29 |
Zedira Gmbh |
Inhibitori transglutaminaza
|
|
IL309077A
(en)
|
2021-06-30 |
2024-02-01 |
Zedira Gmbh |
Transglutaminase inhibitors
|
|
KR20240028466A
(ko)
|
2021-06-30 |
2024-03-05 |
제디라 게엠베하 |
트랜스글루타미나아제 억제제
|
|
CA3235512A1
(en)
|
2021-10-22 |
2023-04-27 |
Xiaobao Yang |
Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
|
|
WO2023086521A1
(en)
|
2021-11-10 |
2023-05-19 |
Biogen Ma Inc. |
Btk inhibitors
|
|
WO2023104155A1
(zh)
|
2021-12-08 |
2023-06-15 |
标新生物医药科技(上海)有限公司 |
E3泛素连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
|
|
JP2025503463A
(ja)
|
2021-12-30 |
2025-02-04 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤をｅ３リガーゼリガンドにコンジュゲートすることによるｂｔｋの分解及び使用方法
|
|
CN118475571A
(zh)
|
2021-12-30 |
2024-08-09 |
百济神州有限公司 |
通过使布鲁顿酪氨酸激酶(btk)抑制剂与e3连接酶配体缀合来降解btk及使用方法
|